Indication
Poor Graft Function
4 clinical trials
8 products
2 drugs
Product
EltrombopagClinical trial
The ELTION Study - A Multicenter Open-label Interventional Study of Eltrombopag in Patients With Poor Graft Function After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Terminated, Estimated PCD: 2020-11-03
Clinical trial
Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II StudyStatus: Recruiting, Estimated PCD: 2024-08-01
Product
Mesenchymal stem cellsClinical trial
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Drug
ASTX727Product
Umbilical Cord BloodDrug
FilgrastimClinical trial
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Decitabine